Patient insights: clinical trial
Bridging clinical trial data with real-world data for unrealized insights into the patient journey.
Patient insights: clinical trial
Bridging clinical trial data with real-world data for unrealized insights into the patient journey.
Up until now clinical trial data and real-world data have existed as separate silos, blocking insights into what’s happening to patients both before and after the trial.
By expanding your vision of each patient beyond the constraints and time period of the clinical trial, you can now take advantage of key missed opportunities in clinical trial development and execution:
- Expand clinical trials to address long-term outcomes
- Lower patient and PI burden by leveraging and linking to RWD
- Incorporate innovative data seamlessly, such as wearables, ePROs
- Gain insights on “lost” patients, both post-trial or after they drop out
- Execute post-marketing surveillance to address regulatory commitments
“Partnering with HealthVerity enables Ciox to deliver research-grade insights with the speed and security required to improve patient experiences and bring lifesaving therapies to market.”
How it works
“We are witnessing the power of clinical trials and real world data linkage in improving patient outcomes across disease areas. We’re excited to expand upon our relationship with HealthVerity to enable life sciences companies to use RWD throughout the clinical development process.”
RWD informs decisions across the clinical lifecycle
Link real-world data from more than 75 major data providers covering 330+ million Americans directly into clinical trial design and execution.
RWD informs decisions across the clinical lifecycle
Link real-world data from more than 75 major data providers covering 330+ million Americans directly into clinical trial design and execution.
“As we explore how robust analyses of real-world data can inform FDA’s response to COVID-19, partners like HealthVerity will help us to identify and evaluate data sources that can be used to answer crucial questions, like how COVID-19 affects different patient populations.”
Prioritize diversity and inclusion per FDA mandate
A breakthrough way to expand the inclusion of minority groups in clinical trials and health plan networks by understanding the racial mix of patients under the care of each provider.
Leverage the Provider Diversity Index to:
- Directly address the FDA draft guidance on minority inclusion in clinical trials
- Identify clinical trial investigators with more diverse patient populations of interest
- Enhance strategies to diversify patient recruiting efforts, especially for COVID-19
- Highlight physicians who are more likely to treat minority patients at higher risk
